EUVIMEDEUVIMED entdecken
Crossref

Incidence, diagnosis, and outcome of immune‐mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura

Cristina Pascual-Izquierdo iD, Julio Del Rio-Garma, Javier de la Rubia, Aurora Viejo, Eva Mingot, Joan Cid iD, Xavier Solanich, Jesús Fernández-Sojo, Jesús Martín-Sánchez iD, Luis Hernández, José María García-Gala, Nieves Alonso und 11 weitere

Journal of Clinical Apheresis · 2021-08 · 36 (4) · 563-573

DOI: 10.1002/jca.21894 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Apheresis, online erschienen am 29.03.2021. Verfasst von Cristina Pascual-Izquierdo und 22 weiteren Autor:innen. Beteiligte Einrichtung: Hospital General Universitario Gregorio Marañón, Madrid, Spain. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease characterized by the presence of anti‐ADAMTS13 autoantibodies. Achieving accurate information on incidence and customary disease management is important to provide appropriate diagnostic and therapeutic resources. The aim of this study was to determine the incidence and outcomes of iTTP in Spain. Study design and methods A cross‐sectional survey was carried out among Spanish hospitals, focused on iTTP patients ≥16 years old attended between 2015 and 2017, and those at follow‐up before that interval. Incidence, prevalence, mortality, refractoriness, exacerbations, treatment complications, relapses, and sequelae were estimated.

Results

Forty‐two hospitals covering roughly 20 million inhabitants answered the survey and reported 203 episodes (138 newly‐diagnosed and 65 relapses), of which 193 (95.1%) were treated. Incidence was 2.67 (95% CI 1.90‐3.45) patients per million inhabitants per year and prevalence 21.44 (95% CI% 19.10‐23.73) patients per million inhabitants. At diagnosis, ADAMTS13 activity and anti‐ADAMTS13 autoantibody were measured in 97% and 84.3% of reported episodes, respectively. Fifteen patients (7.4%) died as a direct consequence of iTTP, 6 of them before receiving any iTTP‐specific treatment. Thirty‐one (16.1%) of the 193 treated episodes were refractory to plasma exchange and corticosteroids, and 51 (26.4%) suffered at least one exacerbation. Conclusion iTTP incidence and prevalence were somewhat higher than those documented in neighboring countries. Together with data on treatments and outcomes, this information will allow us to better estimate what is needed to improve diagnosis and prognosis of iTTP patients in Spain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADAMTS13 ProteinAdultAutoantibodiesCross-Sectional StudiesHematologyHospitalizationHospitalsHumansIncidenceOutcome Assessment, Health CarePlasma ExchangePrevalencePurpura, Thrombotic ThrombocytopenicRegistriesRetrospective StudiesSpainSurveys and QuestionnairesTreatment Outcome

Stichwörter der Autor:innen

ADAMTS13Spainimmune-mediated thrombotic thrombocytopenic purpuraincidencetreatment

Substanzen

AutoantibodiesADAMTS13 ProteinADAMTS13 protein, human

Autor:innen und Institutionen

  • Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Complexo Hospitalario Universitario de Ourense, Spain.
  • Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Hospital Universitario La Paz, Madrid, Spain.
  • Hospital Regional Universitario de Málaga, Spain.

ORCID-Profile: Cristina Pascual-Izquierdo, Joan Cid, Jesús Martín-Sánchez, María Luisa Antelo

Zitieren

APA

Pascual-Izquierdo, C., Del Rio-Garma, J., de la Rubia, J., Viejo, A., Mingot, E., Cid, J., Solanich, X., Fernández-Sojo, J., Martín-Sánchez, J., Hernández, L., García-Gala, J. M., Alonso, N., González, V., Oliva, A., Gómez-Seguí, I., Goterris, R., Guerra, L., García-Candel, F., Fernández-Docampo, M., …, & Spanish Apheresis Group (GEA) and Spanish Thrombotic Thrombocytopenic Purpura Registry (REPTT) (2021). Incidence, diagnosis, and outcome of immune‐mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 36(4), 563-573. https://doi.org/10.1002/jca.21894

Vancouver

Pascual-Izquierdo C, Del Rio-Garma J, de la Rubia J, Viejo A, Mingot E, Cid J, et al. Incidence, diagnosis, and outcome of immune‐mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis. 2021;36(4):563-573. doi:10.1002/jca.21894

BibTeX
@article{PascualIzquierdo2021,
  author = {Pascual-Izquierdo, Cristina and Del Rio-Garma, Julio and de la Rubia, Javier and Viejo, Aurora and Mingot, Eva and Cid, Joan and Solanich, Xavier and Fernández-Sojo, Jesús and Martín-Sánchez, Jesús and Hernández, Luis and García-Gala, José María and Alonso, Nieves and González, Victoria and Oliva, Ana and Gómez-Seguí, Inés and Goterris, Rosa and Guerra, Luisa and García-Candel, Faustino and Fernández-Docampo, Marta and Antelo, María Luisa and Salgado-Barreira, Ángel and Salinas, Ramón and Spanish Apheresis Group (GEA) and Spanish Thrombotic Thrombocytopenic Purpura Registry (REPTT), Spanish Apheresis Group (GEA) and Spanish Thrombotic Thrombocytopenic Purpura Registry (REPTT)},
  title = {Incidence, diagnosis, and outcome of immune‐mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura},
  journal = {Journal of Clinical Apheresis},
  year = {2021},
  volume = {36},
  number = {4},
  pages = {563--573},
  doi = {10.1002/jca.21894}
}
Kostenlos starten →